Home > Publications Database > Propofol versus midazolam sedation in patients with cardiogenic shock - an observational propensity-matched study. > print

001     164041
005     20230915090545.0
024 7 _ |a 10.1016/j.jcrc.2022.154051
|2 doi
024 7 _ |a pmid:35526506
|2 pmid
024 7 _ |a 0883-9441
|2 ISSN
024 7 _ |a 1557-8615
|2 ISSN
024 7 _ |a altmetric:128332203
|2 altmetric
037 _ _ |a DZNE-2022-00704
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Scherer, Clemens
|b 0
245 _ _ |a Propofol versus midazolam sedation in patients with cardiogenic shock - an observational propensity-matched study.
260 _ _ |a Philadelphia, Pa.
|c 2022
|b Saunders
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1653309992_20932
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Benzodiazepines are recommended as first line sedative agent in ventilated cardiogenic shock patients, although data regarding the optimal sedation strategy are sparse. The aim of this study was to investigate the hemodynamic effects of propofol versus midazolam sedation in our cardiogenic shock registry.Mechanically ventilated patients suffering from cardiogenic shock were retrospectively enrolled from the cardiogenic shock registry of the university hospital of Munich. 174 patients treated predominantly with propofol were matched by propensity-score to 174 patients treated predominantly with midazolam.Catecholamine doses were similar on admission but significantly lower in the propofol group on days 1-4 of ICU stay. Mortality rate was 38% in the propofol and 52% in the midazolam group after 30 days (p = 0.002). Rate of ≥BARC3 bleeding was significantly lower in the propofol group compared to the midazolam group (p = 0.008). Sedation with midazolam was significantly associated with ICU mortality.In this observational cohort study, sedation with propofol in comparison to midazolam was linked to a reduced dose of catecholamines, decreased mortality and bleeding rates for patients with cardiogenic shock. Based on this study and in contrast to current recommendations, propofol should be given consideration for sedation in cardiogenic shock patients.
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Anesthetics
|2 Other
650 _ 7 |a Cardiogenic shock
|2 Other
650 _ 7 |a Midazolam
|2 Other
650 _ 7 |a Propofol
|2 Other
650 _ 7 |a Sedation
|2 Other
650 _ 7 |a VA-ECMO
|2 Other
650 _ 2 |a Conscious Sedation
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Hypnotics and Sedatives: therapeutic use
|2 MeSH
650 _ 2 |a Midazolam: therapeutic use
|2 MeSH
650 _ 2 |a Propofol: adverse effects
|2 MeSH
650 _ 2 |a Respiration, Artificial
|2 MeSH
650 _ 2 |a Retrospective Studies
|2 MeSH
650 _ 2 |a Shock, Cardiogenic: drug therapy
|2 MeSH
700 1 _ |a Kleeberger, Jan
|b 1
700 1 _ |a Kellnar, Antonia
|b 2
700 1 _ |a Binzenhöfer, Leonhard
|b 3
700 1 _ |a Lüsebrink, Enzo
|b 4
700 1 _ |a Stocker, Thomas J
|b 5
700 1 _ |a Berghoff, Stefan A
|0 P:(DE-2719)9001700
|b 6
|u dzne
700 1 _ |a Keutner, Alix
|b 7
700 1 _ |a Thienel, Manuela
|b 8
700 1 _ |a Deseive, Simon
|b 9
700 1 _ |a Stark, Konstantin
|b 10
700 1 _ |a Braun, Daniel
|b 11
700 1 _ |a Orban, Mathias
|b 12
700 1 _ |a Petzold, Tobias
|b 13
700 1 _ |a Brunner, Stefan
|b 14
700 1 _ |a Hagl, Christian
|b 15
700 1 _ |a Hausleiter, Jörg
|b 16
700 1 _ |a Massberg, Steffen
|b 17
700 1 _ |a Orban, Martin
|b 18
773 _ _ |a 10.1016/j.jcrc.2022.154051
|g Vol. 71, p. 154051 -
|0 PERI:(DE-600)2041640-4
|p 154051
|t Journal of critical care
|v 71
|y 2022
|x 0883-9441
909 C O |o oai:pub.dzne.de:164041
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)9001700
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-26
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-26
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-29
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J CRIT CARE : 2021
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-29
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2022-11-29
920 1 _ |0 I:(DE-2719)1110008
|k AG Simons
|l Molecular Neurobiology
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1110008
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21